Overview

• Allogene Q3 net loss narrowed to $41.4 mln from $66.3 mln

• Company advances pivotal Phase 2 ALPHA3 trial for LBCL treatment

• Phase 1 RESOLUTION trial with ALLO-329 in autoimmune diseases is enrolling

Outlook

• ALLO-329 proof-of-concept data anticipated in 1H 2026

• Cash runway projected to extend into 2H 2027

Result Drivers

• OPERATING EXPENSES - Declined to $44.9 mln from $71.7 mln a year ago, with R&D expenses down to $31.2 mln and G&A expenses falling to $13.7 mln

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Allogene Therapeutics Inc is $7.50, about 85.2% above its November 5 closing price of $1.11

Press Release: ID:nGNX9JKkLZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)